NCT02251600View on ClinicalTrials.gov

A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Deflazacort

Oral deflazacort administered once daily at 0.9 mg/kg for eight days

Trial Locations (4)

14642

University of Rochester Medical Center, Rochester

60611

Lurie Children's Hospital, Chicago

84112

University of Utah, Salt Lake City

90095

UCLA, Los Angeles

Sponsors

Lead Sponsor

PTC Therapeutics
All Listed Sponsors
lead

PTC Therapeutics

INDUSTRY